Biotechnology Bulletin ›› 2019, Vol. 35 ›› Issue (12): 152-158.doi: 10.13560/j.cnki.biotech.bull.1985.2019-0519
• Orginal Article • Previous Articles Next Articles
HAN Fei1, JIANG Ming-feng1, RAN Rong1, WANG Gang2
Received:
2019-06-12
Online:
2019-12-26
Published:
2019-12-03
HAN Fei, JIANG Ming-feng, RAN Rong, WANG Gang. Research Progress in Fusion Modification of PAS[J]. Biotechnology Bulletin, 2019, 35(12): 152-158.
[1] Kinch, Michael S.An overview of FDA-approved biologics medicines[J]. Drug Discovery Today, 2015, 20(4):393-398. [2] Meibohm B, Zhou H.Characterizing the impact of renal impairment on the clinical pharmacology of biologics[J]. Journal of Clinical Pharmacology, 2012, 52(S1):54S-62S. [3] Corsetti M, Tack J.Naloxegol:The first orally administered, peripherally acting, μ opioid receptor antagonist, approved for the treatment of opioid-induced constipation[J]. Drugs of Today(Barc), 2015, 51(8):479-489. [4] Gabizon AA, Patil Y, La-Beck NM.New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy[J]. Drug Resistance Updates, 2016, 29:90-106. [5] Turecek PL, Bossard MJ, Schoetens F, et al.PEGylation of biopharmaceuticals:a review of chemistry and nonclinical safety information of approved drugs[J]. Journal of Pharmaceutical Sciences, 2016, 105(2):460-475. [6] Bendele A, Seely J, Richey C, et al.Short Communication:Renal tubular vacuolation in animals treated with Polyethylene-Glycol-Conjugated proteins[J]. Toxicological Sciences, 1998, 42(2):152-157. [7] Armstrong JK, Hempel G, Koling S, et al.Antibody against poly(ethylene glycol)adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients[J]. Cancer, 2010, 110(1):103-111. [8] Ganson NJ, Kelly SJ, Scarlett E, et al.Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol)(PEG), in a phase I trial of subcutaneous PEGylated urate oxidase[J]. Arthritis Research & Therapy, 2005, 8(1):R12. [9] Hershfield MS, Ganson NJ, Kelly SJ, et al.Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients[J]. Arthritis Research & Therapy, 2014, 16(2):R63. [10] Judge A, Mcclintock K, Phelps J, et al.Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes[J]. Molecular Therapy, 2006, 13(2):328-337. [11] Schlapschy M, Binder U, Borger C, et al.PASylation:a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins[J]. Protein Engineering Design and Selection, 2013, 26(8):489-501. [12] Breibeck J, Skerra A.The polypeptide biophysics of proline/alanine-rich sequences(PAS):Recombinant biopolymers with PEG-like properties[J]. Biopolymers, 2017:e23069. [13] Binder U, Skerra A.PASylation:A versatile technology to extend drug delivery[J]. Current Opinion in Colloid & Interface Science, 2017, 31:10-17. [14] Nanda P, JagadeeshBabu PE, Raju JR. Production and optimization of site-specific monoPEGylated uricase conjugates using mPEG-maleimide through RP-HPLC methodology[J]. Journal of Pharmaceutical Innovation, 2016, 11(4):279-288. [15] Pfister D, Morbidelli M.Process for protein PEGylation[J]. Journal of Controlled Release, 2014, 180:134-149. [16] Bailon P, Palleroni A, Schaffer CA, et al.Rational design of a potent, long-lasting form of interferon:A 40 kD branched polyethylene glycol-conjugated interferon α-2a for the treatment of Hepatitis C[J]. Bioconjugate Chemistry, 2001, 12(2):195-202. [17] Yu P, Zheng C, Chen J, et al.Investigation on PEGylation strategy of recombinant human interleukin-1 receptor antagonist[J]. Bioorganic and Medicinal Chemistry, 2007, 15(16):5396-5405. [18] Kuhn N, Schmidt CQ, Schlapschy M, et al.PASylated Coversin, a C5-specific complement inhibitor with extended pharmacokinetics, shows enhanced antihemolytic activity in vitro[J]. Bioconjugate Chemistry, 2016, 27:2359-2371. [19] Morath V, Bolze F, Schlapschy M, et al.PASylation of murine leptin leads to extended plasma half-life and enhanced in vivo efficacy[J]. Molecular Pharmaceutics, 2015, 12(5):1431-1432. [20] Pasut G, Veronese FM.State of the art in PEGylation:the great versatility achieved after forty years of research[J]. Journal of Controlled Release, 2012, 161(2):461-472. [21] Deeks ED.Certolizumab Pegol:A review in inflammatory autoimmune diseases[J]. BioDrugs, 2016, 30(6):607-617. [22] Ivens IA, Achanzar W, Baumann A, et al.PEGylated biopharmaceuticals:current experience and considerations for nonclinical development[J]. Toxicologic Pathology, 2015, 43:959-983. [23] Luo X, Hou L, Liang L, et al.Long-acting PEGylated recombinant human growth hormone(Jintrolong)for children with growth hormone deficiency:phase II and phase III multicenter, randomized studies[J]. European Journal of Endocrinology, 2017, 177(2):195-205. [24] Di CS, Binder U, Maier T, et al.High-yield production of PASylated human growth hormone using secretory E. coli technology[J]. BioProcess International Magazine, 2013, 11:30-80. [25] Zvonova EA, Ershov AV, Ershova OA, et al.PASylation technology improves recombinant interferon-β1b solubility, stability, and biological activity[J]. Applied Microbiology and Biotechnology, 2017, 101(5):1975-1987. [26] Bolze F, Morath V, Bast A, et al.Long-Acting PASylated leptin ameliorates obesity by promoting satiety and preventing hypometabolism in leptin-deficient lep(ob/ob)mice[J]. Endocrinology, 2016, 157:233-244. [27] Hedayati MH, Norouzian D, Aminian M, et al.Molecular design, expression and evaluation of PASylated human recombinant erythropoietin with enhanced functional properties[J]. The Protein Journal, 2017, 36(1):36-48. [28] Nelson AL, Reichert JM.Development trends for therapeutic antibody fragments[J]. Nature Biotechnology, 2009, 27(4):331-337. [29] Reichert JM.Marketed therapeutic antibodies compendium[J]. MAbs, 2012, 4:413-415. [30] Holliger P, Hudson PJ.Engineered antibody fragments and the rise of single domains[J]. Nature Biotechnology, 2005, 23(9):1126-1136. [31] Dennis MS, Jin H, Dugger D, et al.Imaging tumors with an albumin-binding fab, a novel tumor-targeting agent[J]. Cancer Research, 2007, 67(1):254-261. [32] Thurber GM, Zajic SC, Wittrup KD.Theoretic criteria for antibody penetration into solid tumors and micrometastases[J]. Journal of Nuclear Medicine, 2007, 48(6):995-999. [33] Mendler CT, Friedrich L, Laitinen I, et al.High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation[J]. MAbs, 2015, 7(1):96-109. [34] Falvo E, Tremante E, Arcovito A, et al.Improved doxorubicin encapsulation and pharmacokinetics of ferritinfusion protein nanocarriers bearing proline, serine, and alanine elements[J]. Biomacromolecules, 2016, 17(2):514-522. [35] 曹阳, 包永明, 安利佳, 等. 乳铁蛋白研究现状[J]. 食品科学, 2002, 23(12):132-138. [36] Lerchner A, Daake M, Jarasch A, et al.Fusion of an alcohol dehydrogenase with an aminotransferase using a PAS linker to improve coupled enzymatic alcohol-to-amine conversion[J]. Protein Engineering Design and Selection, 2016, 29(12):557-562. [37] Sadry SA, Drucker DJ.Emerging combinatorial hormone therapies for the treatment of obesity and T2DM[J]. Nature Reviews Endocrinology, 2013, 9(7):425-433. [38] Kontermann RE.Half-life extended biotherapeutics[J]. Expert Opinion on Biological Therapy, 2016, 16:903-915. [39] Huang YS, Wen XF, Wu YL, et al.Engineering a pharmacologically superior form of granulocyte-colony-stimulating factor by fusion with gelatin-like-protein polymer[J]. European Journal of Pharmaceutics & Biopharmaceutics, 2010, 74:435-441. [40] Olsen D, Yang C, Bodo M, et al.Recombinant collagen and gelatin for drug delivery[J]. Advanced Drug Delivery Reviews, 2003, 55(12):1547-1567. [41] Cleland JL, Geething NC, Moore JA, et al.A novel long-acting human growth hormone fusion protein(vrs-317):enhanced in vivo potency and half-life[J]. Journal of Pharmaceutical Sciences, 2012, 101(8):2744-2754. [42] Podust VN, Balan S, Sim BC, et al.Extension of in vivo half-life of biologically active molecules by XTEN protein polymers[J]. Journal of Controlled Release, 2016, 240:52-66. [43] Geething NC, To W, Spink BJ, et al.Gcg-XTEN:An improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose[J]. PLoS One, 2010, 5(4):e10175. [44] Alters SE, Mclaughlin B, Spink B, et al.GLP2-2G-XTEN:a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn’s[J]. PLoS One, 2012, 7(11):e50630. [45] Bain V.A phase 2 study to assess antiviral response, safety, and pharmacokinetics of Albuferon^ in IFN-alfa naive subjects with genotype 1 chronic hepatitis C[J]. Journal of Hepatology, 2005, 42(Suppl 2):9. [46] Sato C, Kitajima K.Polysialic acid[J]. Glycoscience Biology & Medicine, 2014:519-528. |
[1] | LI Huan-min, GAO Feng-tao, LI Wei-zhong, WANG Jin-qing, FENG Jia-li. Progress in Research and Application of Natural Bio-materials as Immobilized Carriers [J]. Biotechnology Bulletin, 2023, 39(7): 105-112. |
[2] | LI Yu-zhen, MEI Tian-xiu, LI Zhi-wen, WANG Qi, LI Jun, ZOU Yue, ZHAO Xin-qing. Advances in Genomic Studies and Metabolic Engineering of Red Yeasts [J]. Biotechnology Bulletin, 2023, 39(7): 67-79. |
[3] | WANG Xiao-mei, YANG Xiao-wei, LI Hui-shang, HE Wei, XIN Zhu-lin. Development Status of Synthetic Biology in Globe and Its Enlightenment [J]. Biotechnology Bulletin, 2023, 39(2): 292-302. |
[4] | SUN De-quan, LU Xin-hua, LI Wei-ming, HU Yu-lin, DUAN Ya-jie, PANG Zhen-cai, HU Hui-gang. Application of Mesoporous Silica Nanoparticles in Agriculture [J]. Biotechnology Bulletin, 2022, 38(5): 228-239. |
[5] | XIONG He-li, SHA Qian, LIU Shao-na, XIANG De-cai, ZHANG Bin, ZHAO Zhi-yong. Application of Single-cell Transcriptome Sequencing in Animals [J]. Biotechnology Bulletin, 2022, 38(3): 226-233. |
[6] | LUO Xue-cong, AN Meng-nan, WU Yuan-hua, XIA Zi-hao. Applications of Recombinase Polymerase Amplification in Plant Virus Detection [J]. Biotechnology Bulletin, 2022, 38(2): 269-280. |
[7] | XU Jin-yi, NA Bin-bin, LIU Shun, CHEN Chao, SUN Hong, ZHENG Yu-long. Excellent Lactic Acid Bacteria for Silage and Their Application [J]. Biotechnology Bulletin, 2021, 37(9): 39-47. |
[8] | ZHANG Qian, XUE Yu, HE Ling-xiao, WU Jiang, CHENG Yu-yuan, YANG Tie-zhao, DING Yong-le, XU Shi-xiao, XUE Gang. Effects of Planting Density,Amount of Nitrogen Application and Left Leaf Number on the Highlighting of Flavor Style in Qushou 1 [J]. Biotechnology Bulletin, 2021, 37(6): 24-35. |
[9] | ZHAI Xu-hang, LI Xia, YUAN Ying-jin. Research Progress of Lignocellulose Pretreatment and Valorization Method [J]. Biotechnology Bulletin, 2021, 37(3): 162-174. |
[10] | HE Yang, YU Qiao-ling, WANG Jun, QIN Chuan-jie, LI Hua-tao. Advances in Prokaryotic Expression Gene of Tilapia [J]. Biotechnology Bulletin, 2021, 37(2): 195-202. |
[11] | XUE Fan-zheng, HUANG Hai-chen, WU Fu-quan, LI Xiao-min, WU Xiao-ping, FU Jun-sheng. Research Status and Industrial Application of Fungal Melanin [J]. Biotechnology Bulletin, 2021, 37(11): 32-41. |
[12] | HU Zi-yuan, XIA Qiang. Advances in the Histology Study,Function and Application of Insect Intestinal Flora [J]. Biotechnology Bulletin, 2021, 37(1): 102-112. |
[13] | WANG Xiao-fang, HOU Yu-gang, YANG Ke-ming, WANG Jia-ning, WEI Zhong, XU Yang-chun, SHEN Qi-rong. Isolation of Specific Phage of Ralstonia solanacearum and Its Effects on Control of Soil-borne Bacterial Wilt Disease [J]. Biotechnology Bulletin, 2020, 36(9): 194-201. |
[14] | HUANG Kun-long, SU Xiao-yun, YAO Bin. Fusion Expression of Somatostatin with a Thermostable Xylanase and Characterization of the Fusion Protein [J]. Biotechnology Bulletin, 2020, 36(9): 235-243. |
[15] | SHI Xiao-ping, CHEN Yin-ping, YAN Zhi-qiang, LUO Yong-qing, LI Yu-qiang, DING Jun-gang, XIE Hai-fan. Research Progress on Plant Allelopathy [J]. Biotechnology Bulletin, 2020, 36(6): 215-222. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||